Evan A Stein
Overview
Explore the profile of Evan A Stein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
115
Citations
5695
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raal F, Mehta V, Kayikcioglu M, Blom D, Gupta P, Elis A, et al.
Lancet Diabetes Endocrinol
. 2025 Jan;
13(3):178-187.
PMID: 39870096
Background: Lerodalcibep, a small binding anti-PCSK9 protein (adnectin), showed effective LDL cholesterol reduction in heterozygous familial hypercholesterolaemia. We aimed to assess the safety and efficacy of lerodalcibep and evolocumab in...
2.
Klug E, Llerena S, Burgess L, Fourie N, Scott R, Vest J, et al.
JAMA Cardiol
. 2024 Jul;
9(9):800-807.
PMID: 38958989
Importance: Recent changes in national and international lipid guidelines for reducing cardiovascular events recommend additional drugs, greater reductions, and lower targets for low-density lipoprotein cholesterol (LDL-C) if not attained with...
3.
Schludi B, Giugliano R, Sabatine M, Raal F, Teramoto T, Koren M, et al.
J Clin Lipidol
. 2022 Jun;
16(4):538-543.
PMID: 35760720
LDL-C is the pivotal risk factor for atherosclerotic cardiovascular disease, and the benefit from LDL-C lowering is proportional to the magnitude of reduction. Clinical trials demonstrate that evolocumab reduces LDL-C...
4.
Turner T, Stein E
Lancet Diabetes Endocrinol
. 2022 Apr;
10(5):301-303.
PMID: 35378071
No abstract available.
5.
Vallejo-Vaz A, Packard C, Ference B, Santos R, Kastelein J, Stein E, et al.
Atherosclerosis
. 2021 Jan;
320:1-9.
PMID: 33497862
Background And Aims: Trial evidence for the benefits of cholesterol-lowering is limited for familial hypercholesterolemia (FH) patients, since they have not been the focus of large outcome trials. We assess...
6.
Raal F, Bahassi E, Stevens B, Turner T, Stein E
Arterioscler Thromb Vasc Biol
. 2020 Sep;
40(11):2747-2755.
PMID: 32878475
Objective: Due to gene founder effects, familial hypercholesterolemia (FH) has a prevalence of ≈1:80 in populations of Afrikaner ancestry and is a major contributor to premature atherosclerotic cardiovascular disease in...
7.
Santos R, Stein E, Hovingh G, Blom D, Soran H, Watts G, et al.
J Am Coll Cardiol
. 2020 Feb;
75(6):565-574.
PMID: 32057369
Background: Proprotein convertase subtilisin/kexin type 9 inhibitor therapy is a treatment option for patients with familial hypercholesterolemia (FH) who are unable to reach low-density lipoprotein cholesterol (LDL-C) goals. Objectives: The...
8.
Cho L, Dent R, Stroes E, Stein E, Sullivan D, Ruzza A, et al.
Cardiovasc Drugs Ther
. 2018 Aug;
32(4):365-372.
PMID: 30073585
Purpose: Evolocumab reduced low-density lipoprotein cholesterol (LDL-C) in 12-week trials in statin-intolerant patients (GAUSS-1 and GAUSS-2); however, the persistence of efficacy during longer-term treatment is unknown. This subset analysis of...
9.
Martin S, Giugliano R, Murphy S, Wasserman S, Stein E, Ceska R, et al.
JAMA Cardiol
. 2018 Jun;
3(8):749-753.
PMID: 29898218
Importance: Recent studies have shown that Friedewald underestimates low-density lipoprotein cholesterol (LDL-C) at lower levels, which could result in undertreatment of high-risk patients. A novel method (Martin/Hopkins) using a patient-specific...
10.
Mach F, Ray K, Wiklund O, Corsini A, Catapano A, Bruckert E, et al.
Eur Heart J
. 2018 May;
39(27):2526-2539.
PMID: 29718253
Aims: To objectively appraise evidence for possible adverse effects of long-term statin therapy on glucose homeostasis, cognitive, renal and hepatic function, and risk for haemorrhagic stroke or cataract. Methods And...